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Abstract: The human body is naturally colonized by a huge number of different commensal microbial
species, in a relatively stable equilibrium. When this microbial community undergoes dysbiosis
at any part of the body, it interacts with the innate immune system and results in a poor health
status, locally or systemically. Research studies show that bacteria are capable of significantly
influencing specific cells of the immune system, resulting in many diseases, including a neoplastic
response. Amongst the multiple different types of diseases, pancreatic cancer and liver cirrhosis
were significantly considered in this paper, as they are major fatal diseases. Recently, these two
diseases were shown to be associated with increased or decreased numbers of certain oral bacterial
species. These findings open the way for a broader perception and more specific investigative
studies, to better understand the possible future treatment and prevention. This review aims
to describe the correlation between oral dysbiosis and both pancreatic cancer and liver cirrhotic
diseases, as well as demonstrating the possible diagnostic and treatment modalities, relying on
the oral microbiota, itself, as prospective, simple, applicable non-invasive approaches to patients,
by focusing on the state of the art. PubMed was electronically searched, using the following key
words: “oral microbiota” and “pancreatic cancer” (PC), “liver cirrhosis”, “systemic involvement”,
and “inflammatory mediators”. Oral dysbiosis is a common problem related to poor oral or systemic
health conditions. Oral pathogens can disseminate to distant body organs via the local, oral blood
circulation, or pass through the gastrointestinal tract and enter the systemic circulation. Once oral
pathogens reach an organ, they modify the immune response and stimulate the release of the
inflammatory mediators, this results in a disease. Recent studies have reported a correlation between
oral dysbiosis and the increased risk of pancreatic and liver diseases and provided evidence of the
presence of oral pathogens in diseased organs. The profound impact that microbial communities have
on human health, provides a wide domain towards precisely investigating and clearly understanding
the mechanism of many diseases, including cancer. Oral microbiota is an essential contributor
to health status and imbalance in this community was correlated to oral and systemic diseases.
The presence of elevated numbers of certain oral bacteria, particularly P. gingivalis, as well as
elevated levels of blood serum antibodies, against this bacterial species, was associated with a
higher risk of pancreatic cancer and liver cirrhosis incidence. Attempts are increasingly directed
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towards investigating the composition of oral microbiome as a simple diagnostic approach in multiple
diseases, including pancreatic and liver pathosis. Moreover, treatment efforts are concerned in the
recruitment of microbiota, for remedial purposes of the aforementioned and other different diseases.
Further investigation is required to confirm and clarify the role of oral microbiota in enhancing
pancreatic and liver diseases. Improving the treatment modalities requires an exertion of more effort,
especially, concerning the microbiome engineering and oral microbiota transplantation.
Keywords: oral microbiota; dysbiosis; inflammatory mediators; pancreatic cancer; liver cirrhosis;
risk; probiotics
1. Introduction
The oral microbiota refers to a highly varied and complicated ecosystem of bacteria, fungi, viruses,
and archaea. These organisms naturally colonize the healthy oral cavity [1,2] in a relatively stable
equilibrium [3] that includes more than seven hundred diverse bacterial species, one hundred fungal
species, as well as a large viral population [4]. These microorganisms inhabit the ecological niches of
both hard and soft oral tissues, in the form of biofilms [5]. Diverse microbial species prefer to inhabit
specific niches with differing surface textures and functions [6,7].
Bacteria are generally classified within five main phyla: (i) Firmicutes, (ii) Bacteroidetes,
(iii) Actinobacteria, (iv) Proteobacteria, and finally (v) Verrucomicrobia [8]. Prevalent oral groups include
Streptococcus, Neisseria, Veillonella, Actinomyces, and other obligate anaerobes [6]. Oral bacteria include
aerobic, anaerobic or facultative anaerobic bacteria with the Fusobacterium, Veillonella, and the Streptococci
genera [6], as well as a plethora of species, not-yet cultivated and identified by means of the next generation
sequencing technologies.
While the role of oral bacteria in human health and disease is increasingly well-characterized,
the role of oral virome and mycobiome, remain largely uncharacterized [2,4]. The most common
oral fungi are the Candida species that causes oral candidiasis when it undergoes dysbiosis.
The common oral viruses include Herpes viruses, such as the herpes simplex virus 1 (HSV-1),
the Cytomegalovirus (CMV), and the Epstein-Barr virus (EBV), and have been suggested to be associated
with periodontitis [2,4].
The human body harbors distinct microbiomes, in different areas, that are substantial to
homeostasis preservation. As long as these microorganisms maintain equilibrium at the appropriate
site and function, they benefit the body systems. The microbiota’s benefits include support during
digestion, the synthesis of vitamins B and K, prevention against pathogenic colonization [9–12],
and a better outcome of immunotherapy [13]. Much evidence demonstrates the oral microbes’
role in balancing health conditions, including immune response, carcinogenesis, metabolic activity,
and nutrient digestion [13–15].
Microbial equilibrium is preserved by the host’s immune system, which inhibits invasion of these
organisms within the local tissue [9–11]. Within the oral cavity, microbial balance is maintained by
several mechanisms that reduce their concentrations. These include the constant shedding of epithelial
lining cells and salivary secretions as an example of immunoglobulins IgM, IgG, and IgA. Furthermore,
agglutinins contained in the saliva, histatins, lactoferrins, and lysozymes prevent microbial insult [5,16].
Moreover, the majority of oral herpes viruses are bacteriophages contributing to the maintenance
of a bacterial balance. Most of twenty-eight phages are part of the Caudovirus families: Siphoviridae
(recognized as lysogenic), Myoviridae (sometimes lytic), and Podoviridae (mostly lytic) [2,17]. However,
it should be considered that the virus communities belonging to the oral cavity can largely change in
relation to the host sex [18].
Conversely, saliva is also a substantial source of proteins, glycoproteins, and other nutrients that
preserve microbial ecology [5].
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Increased or decreased bacterial levels act as biomarkers of healthy/unhealthy microbial
performance [19]. Speaking about oral viral communities, it is well-known that they can cause a
severe immune reaction in the host. Accordingly, it can be speculated that they have a crucial role in
the preservation of oral immunity and in the rise of diseases [2,18,20].
2. Gut Microbiota and Immune Response in Cancer
Novel researches detect a major interactive network, through which the host gut bacteria interact
with the immune cells result in a good or bad health status [21].
Recent studies argue that this microbial-immune network correlates gut bacteria with the
whole-body health and the failure of immune homeostasis manifest significant impact on various
diseases, which might result in cancer [22–24].
Indeed, the neoplasm consequence is not exclusively dependent on the host genotype but
the immune system efficiency also plays a significant role. The immune system’s role in cancer
was explained by previous studies that were carried out by applying enteropathogenic bacteria
like Helicobacter hepaticus (H. hepaticus) on the immune-deficient mice that lack functional T and B
lymphocytes. These experimental studies revealed both the carcinogenic incidence/suppression
induced via microbe-innate immune system interaction [24–26].
Amongst the whole immune cells, neutrophils manifest a particular influence, as they play a key
role in the development and growth of cancer [27,28].
Clinical investigative statistics show a correlation between high blood (neutrophil:lymphocyte)
ratio and poor cancer prognosis, including a higher possibility of metastatic tendency [29,30].
In addition, many studies have demonstrated that poor neoplastic prognosis is related to the existence
of neutrophils in the tumor microenvironment [29–31] and animal models have revealed the neutrophil
contributions in the different stages of cancer [29,31,32]. This might be attributed to the crucial
role of neutrophils in boosting tumor growth and metastasis [29]. One of the different modalities
of neoplasm enhancement is achieved via releasing cytokines, such as IL1-β, IL-17, and IL-23 by
the tumor inflammatory environment, as well as the tumor cells. Therefore, up-regulation of the
granulocyte colony stimulating factor (G-CSF) takes place. Accordingly, neutrophils are produced
and mobilized from the bone marrow, into the peripheral blood circulation, as an urgent demand.
It has been observed that during expansion of the mature/immature neutrophils, T-cell proliferation is
suppressed by the so-called myeloid-derived suppressor cells (MDSCs) and, thereby, the anti-tumoral
influence of the T-cells becomes annulled [21,33–35]. Moreover, when neutrophils infiltrate a tumor,
these tumor-associated neutrophils (TANs) shape the tumoral microenvironment by releasing growth
factors, chemokines, and serine proteases, which encourage tumoral motility, migration, invasion,
and expansion. These metastatic events are further supported by the neutrophils’ role in facilitating
the tumoral cell intravasation, adhesion in the endothelium, and extravasation [29,32,36].
3. Systemic Involvement by Oral Bacteria
Dysbiosis refers to poor microbial adaptation or imbalance, on or inside the body [8], which results
in a poor health status. Since the oral cavity is considered to be the leading entryway to the human
body, the microbiota that reside within this ecological niche are very likely to expand to the various
body areas [37]. When oral bacteria undergo dysbiosis, they become pathogenic and can damage
the oral mucous membrane and use it as a passageway to reach the blood stream [38]. Whether oral
bacteria migrate and colonize distant diseased body-sites or the same clonal origin are normally found
in other body-sites, remains unclear. Regarding the potential dissemination of oral bacteria, throughout
the body, some researchers have suggested bacteria continuously migrate via swallowing or the blood
circulation system, within the oral cavity [39–41]. Thereafter, systemically these pathogens generate
exaggerated quantities of the inflammatory mediators, and modify the body’s immune response.
The inflammatory mediators released by the immune system include activated complement product
C3a, interleukin 6 (IL-6), and the acute-phase reactant secretory phospholipase A2 (sPLA2) [42,43]
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Consequently, this process can promote certain systemic diseases [44], including cardiovascular
diseases, diabetes, metabolic syndrome [5], and organ abscesses at distant sites [38,45].
Along these lines, recent studies have supposed a correlation, via bacterial dissemination,
between oral dysbiosis and a risk of both pancreatic cancer (PC) and liver disease.
3.1. Pancreatic Cancer (PC)
PC is a major fatal malignant disease that occupies the fourth ranking [46] among
cancer-associated mortalities, worldwide [46]. The disease’s high fatality is attributed to difficulties
associated with early diagnosis and shortages in efficient therapy, stemming from drug resistant
neoplasms. In addition, PC has the propensity to vigorously spread and metastasize to regional lymph
nodes and distant organs. Each of these factors limit the five-year survival rate to less than 5% [46].
Many well-known risk factors contribute to PC—alcohol consumption, chronic pancreatitis,
genetic mutations, environmental hazards, and cigarette smoking. Cigarette smoking serves as the
major cause for pancreatic adenocarcinoma—approximately 25% cases are attributed to cigarette
smoking. Increased risk of PC also relates to long-term type 2 diabetes mellitus present for more than
10 years. Furthermore, recent onset of diabetes might be an initial indicator of PC. Many previous
studies have reported associations between increased PC-risk and increased body mass index
(BMI) [47]. Other studies state that persons with cirrhosis appear to be at higher risk of PC [48].
3.1.1. Pathophysiology of PC
Chronic pancreatitis, an inflammatory disease that precedes PC, is characterized by progressive
fibrotic destruction of the pancreatic secretory parenchyma. Regardless of the disease’s diverse
risk factors, pathogenic processes commonly include inflammation, pancreatic duct obstruction or
necrosis/apoptosis. These cumulative processes subsequently distort pancreatic lobular morphology,
modify the islet arrangement, and deform pancreatic ducts. These irreversible structural alterations
impair both endocrine and exocrine pancreatic functions, and ultimately, result in neoplasm. Generally,
disease prevalence largely reflects culture and geography [49].
3.1.2. Association between PC and Oral Dysbiosis
Oral environmental balance plays a crucial role in oral health, and when oral dysbiosis occurs,
dental diseases can result, such as dental caries and periodontal disease.
Many recent epidemiological investigations have identified an increased PC-risk in association
with poor oral health conditions [50–54]. Since oral health status is strictly affected by the oral microbial
equilibrium and activities, researchers have hypothesized that this association between PC-risk and
oral health conditions might stem from the oral bacterial status [55,56]. In support of this hypothesis,
a previous study has demonstrated the presence of elevated levels of blood serum antibodies for select
oral pathogens—namely, Porphyromonas gingivalis—that were accompanied with a two-fold higher risk
of PC [56,57].
To address this concern, direct assessment of oral bacterial samples was carried out using
high-throughput genomic sequencing. Results revealed that specific gram negative oral bacteria
are associated with a three-fold increased risk of PC. The study also identified these bacteria in the
human pancreatic duct. Similarly, recent cohort studies have reported that individuals with greater
circulating antibodies, for multiple oral bacteria, are at greater risk of PC [57]. In a 2013 study conducted
by Michaud et al., the levels of ATTC 53978 antibodies against P. gingivalis were found to be higher in
the four hundred and five patients with PC, as compared to the healthy volunteers [58].
Although direct correlation between PC and oral bacteria has not yet been established, a patient
with a history of periodontal disease associated with circulating antibodies, against specific oral
pathogenic bacteria, was shown to be accompanied by an increased risk of PC. P. gingivalis and
Aggregatibacter actinomycetemcomitans are well-known keystone oral pathogens that initiate periodontal
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diseases and a subsequent tooth loss [59–61]. Some studies have argued that this condition is
accompanied by an increased risk of PC [50–54].
PC-risk increases with the carriage of the periodontal pathogens P. gingivalis and
A. actinomycetemcomitans. Previous research has found that P. gingivalis can invade the host immune
system and disrupt signaling pathways, via cytokine and receptor degradation [62]. Furthermore,
researchers have recently demonstrated that both P. gingivalis and A. actinomycetemcomitans are capable
of initiating Toll-like receptor (TLR) signaling pathways, and that TLR activation is a crucial promoter
of PC in animal models [57,62].
One previous study conducted by Barton et al. demonstrated that PC patients are mostly affected
by a specific mutation in the cell cycle controller p53 that is related to the loss of an arginine [63].
A possible explanation comes from a recent study that showed how the bacterial peptidyl
arginine deaminase (PAD) enzyme can be responsible for this mutation, when present in PC patients.
Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, and Treponema denticola have been
shown to hold the PAD enzyme; its activity can be linked to the modification of the Pro allele
p53Arg72-Pro that is considered to be a risk factor in PCPC cases [64,65].
On the other hand, greater multitudes of the Fusobacterium and its genus Leptotrichia are associated
with a lower risk of PC. However, the other Fusobacteria genus (Alloprevotella) might be accompanied
by PC-risk [62]. As an opportunistic pathogen, Leptotrichia is responsible for many infectious
diseases [62,66,67], including periodontitis, osteomyelitis, bacteremia, pneumonia, lung abscess,
and endocarditis. These bacteria elicit an immune response that results in elevated levels of serum
antibodies for this bacterial type [66]. Some have suggested that protection against PC is associated
with the immune response elicited by these bacteria [62].
The abundance of various oral bacteria and their relation to PC-risk is summarized in Table 1.
Table 1. Common oral bacteria and their associated pancreatic cancer risk.
Bacteria Pancreatic Cancer Risk
P. gingivalis Increased risk
A. actinomycetemcomitans Increased risk
Tannerella forsythia Not associated
Prevotella intermedia Not associated
Fusobacteria
Genus Leptotrichia Decreased risk
Genus Alloprevotella Increased risk
3.1.3. Presence of Oral Bacteria within the Pancreas
An investigative study for patients with calcific pancreatitis was conducted by Swidsinski et al. [68],
using fluorescence in situ hybridization. They revealed the presence of dense multispecies bacterial
biofilm comprised of different types of oral bacteria, in the pancreatic duct. These bacterial species
were also found in the brains of Alzheimer’s patients [69], distal esophageal tissue [70], atherosclerotic
plaques [71,72], and the feto-placental unit [73]. Whether oral bacteria migrate and colonize distant
diseased body sites or the same clonal origin are normally found in other body sites, remains unclear.
Regarding the potential dissemination of oral bacteria throughout the body, some researchers have
suggested bacteria continuously migrate, via swallowing, or the blood circulation system within the
oral cavity [39–41].
Further investigative study is required to clearly identify this correlation and clarify the immune
system’s role in PC.
3.2. Liver Cirrhosis
Liver cirrhosis is the histological transformation of hepatic tissue developed by the regenerative
nodular tissue formation. This nodular tissue becomes surrounded by fibrous bands, as a result of
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the chronic hepatic injury that lasts for several years or decades and, consequently, causes portal
hypertension and end-stage liver disease [74,75]. It is one of the most widespread health conditions
related to morbidity and resulting in mortality [74].
Several diverse etiological factors contribute to liver cirrhosis. The most predominant include
viral hepatitis, alcoholic liver disease (ALD), and nonalcoholic fatty liver disease/nonalcoholic
steatohepatitis (NAFLD/NASH) [76,77]. Recent studies have presented some evidence of a possible
relationship between liver diseases and dysbiosis of oral microbiota [78–85].
3.2.1. Pathophysiology of Liver Cirrhosis
Regardless of etiologic factors, liver pathosis is primarily triggered by inflammation that produces
disease-specific inflammatory mediators and causes hepatocellular changes.
Liver cirrhotic transformation results when the upregulation of these mediators excites
hepatocytes, hepatic stellate cells (HSCs), Kupffer cells, cholangiocytes, and hepatic T cells, and trigger
the production of inflammatory molecules, like TNF, TGF-β1, and IL-6. Once the HSCs are stimulated
by these inflammatory mediators, they begin to produce myofibroblasts, which in turn develop
collagen and result in fibrosis and cirrhosis, over time [86,87].
3.2.2. Association between Liver Disease and Oral Dysbiosis
While the correlation between liver and periodontal diseases has not yet been proven [88],
clinical cases demonstrate an association between periodontitis and some types of liver pathosis,
including cirrhosis, hepatocellular carcinoma, and pre-cirrhotic NAFLD [80]. Aberg and colleagues
presented a relation between the Periodontal disease and chronic liver disease progression, suggesting
that oral disease plays a role in cirrhosis [81].
Another study conducted by Yoneda et al. reveals that P. gingivalis (one of the most common
periodontal pathogens) infection was mostly observed in the NAFLD positive patients, rather than
the NAFLD negative patients [82]. In addition, Yoneda et al. demonstrated through an in vivo
mice model that the P. gingivalis infection was effective in promoting NAFLD progression towards
NASH. Moreover, Nagao et al. inspected the correlation within periodontal diseases and liver fibrosis
advancement in hepatitis B- and C-related cirrhosis [83]. In fact, they demonstrated that the P. gingivalis
fimbrillin A genotype was strongly present in the saliva of patients affected by liver cirrhosis [81,84,85].
Their research stated that periodontal diseases might be accompanied by a viral liver disease
progression [83]. After considering various cirrhosis etiologies, periodontitis predominance was
reported as higher among alcoholic cirrhosis patients [81,84,85].
3.2.3. Mechanism of the Oral Bacteria Dissemination and Liver Affection
An investigative study of oral microbial functionality documented how endotoxin levels as well
as their ability to fold with protein, were much higher in cirrhotic patients rather than healthy ones.
This may indicate the oral-gut-liver axis as the main reason of the inflammation cascade activation
load in cirrhotic patients [79]. When intestinal permeability is impaired, the gut could likely act as
a hallway between the oral cavity and the liver; bacteria metabolites and inflammation activators
could be directly transmitted to the systemic blood circulation [88]. Bacteria and their products
could then access the liver through the portal vein and react with the innate sensors (TLRs and
NLRs) of hepatocytes and Kupffer cells, inducing inflammatory mediator release and consequently
causing the cirrhosis development [89,90]. A prospective study conducted by Qin et al., matched
fecal bacteria of patients with liver cirrhosis with healthy control participants. The investigation
revealed increased levels of Streptococcus and Veillonella species from the feces of patients affected by
cirrhosis [91]. Accordingly, the authors concluded that oral bacteria likely disseminate within or invade
the gut, due to modifications in intestinal pH or bile acid (BA) dysregulation associated with cirrhosis.
Moreover, cirrhosis is associated with gastric acid and bile secretion impairment, which facilitates the
oral microbes’ translocation within the gut. Another study focused on investigating oral bacterial
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extension to the liver, during the administration of omeprazole, a proton pump inhibitor (PPI) that
decreases stomach digestive acid secretion. When the gastric pH was raised, bacteria were able to pass
without being killed [92].
4. Diagnosis of PC and Liver Cirrhosis by Oral Microbiota Status
There is a well-established, tight relationship between oral and general systemic health
conditions [93]. Some studies posit that oral microbial dysbiosis may act as an indicator of the disturbed
health conditions [94,95], and microbial alteration has been shown to accompany the increased PC risk,
chronic inflammatory liver diseases, and hepatocellular carcinoma [96] The role of the microbiota may
be of help in diagnosis, prognosis, and therapy, and clinical investigations are increasingly rely on oral
microbial analysis, also, for systemic disease diagnosis [93]. Oral microbiome investigation is most
commonly based on the 16S ribosomal RNA (rRNA) gene sequencing. Tongue coat investigations
have revealed noticeably higher levels of Oribacterium and Fusobacterium, in liver cirrhotic patients,
compared to healthy controls [96,97]. While salivary investigative studies have shown increased
Enterobacteriaceae and Enterococcacea in cirrhotic patients [98]. Examinations of mouth wash samples
have demonstrated that an increased abundance of P. gingivalis and A. actinomycetemcomitans, associated
with a decreased relative abundance of Fusobacterium and its genus Leptotrichia, were subsequently
related to an increased PC-risk [62]. These findings might provide prospective non-invasive diagnostic
biomarkers in cirrhotic and pancreatic diseased patients [96].
5. Treatment Efforts
5.1. Engineering and Harnessing the Microbiome
Microbiome-based therapeutics, prepared to ameliorate human health by altering the associated
microbial communities, could utilize modulatory, additive, or subtractive techniques. Modulatory
therapies encompass modifying the activity or composition of the endogenous microbiota,
by administering prebiotics or nonliving agents [99]. Additive therapies supply the microbiota with
engineered or natural microorganisms [100–103], given either, individually, or as groups of strains.
Subtractive therapies aim at altering the host interactions by removing certain microbiome members.
In the not so-distant future, both subtractive and additive means might be utilized, jointly, to attain a
larger effectiveness on the microbiome [104].
5.1.1. Additive Approaches
Considerable health advantages have been accredited to natural, human-associated microbes.
Lactobacillus spp., E. coli, and Bifidobacterium spp. have the prospect to cure a diversity of illness [105–108]
which, indeed, can be found in over the-counter probiotics [104].
Probiotics Therapy
Probiotics can be defined as living microorganisms that provide health-beneficial roles,
when properly administered to the host [109]. These bacteria primarily fall within the lactic acid
bacteria [LAB] category, such as Lactobacillus spp. and Bifidobacterium spp. [110]. They are generally
ingested with fermented foods or administered as dietary supplements. Several researchers have
provided evidence that among gut microbiota, probiotics play a prospective role in preventing cancer
development at all stages.
Interestingly, the pancreas does not host a particular microbiome; nevertheless, it is extensively
influenced by gut dysbiosis. As mentioned above, bacterial endotoxins and antigens pass through the
portal blood and stimulate pancreatic macrophages, to release inflammatory cytokines, like interleukins
and tumor necrosis factors in necrotic pancreatic tissues. Inflammatory cytokines are one of the principle
causes of chronic pancreatitis and subsequent pancreatic carcinogenesis. As a result, commensal
microbiota, such as probiotics, have been increasingly utilized for both PC-prevention and treatment.
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Scientific studies have demonstrated that gut microflora roles are positively-affected by probiotics,
which are therapeutically influenced via the immune system stimulation and modulation of the
indigenous intestinal microflora composition and metabolic activity. This impact in turn prevents
bacterial overgrowth and inhibits pathogen colonization [111]. Other studies have proposed strong
evidence that not only supports the preventive roles of probiotics—including LAB—but also confirms
their implicit ability to bind or metabolize the mutagenic carcinogens [112,113].
Other investigative studies have revealed one probiotic’s ability to alleviate fungal mycotoxins
and toxic heavy metals, which may act as potential pancreatic oncogenic factors [114–117].
These investigations were performed by involving Propionibacterium, a well-known dairy probiotic.
Thus, PC risk could potentially be lowered by decreasing the bioavailability of these neoplastic
components [118].
Evidence demonstrates probiotics’ influences on the innate microbiome in non-cirrhotic
patients [119]; nevertheless, further investigation is required to determine an influence of probiotics
among cirrhotic patients.
A randomized controlled trial (RCT) demonstrated that when volunteers received a dose of
Lactobacillus rhamnosus GG (LGG), twice a day, via oral administration for an eight weeks total, the level
of Enterobacteriaceae was noticeably reduced while, on the opposite, the autochthonous Clostridiales
incertae sedis XIV and Lachnospiraceae were increased in the feces [120]. These evidences were ascribed
as a loss of dysbiosis; in fact, after eight weeks of LGG administration, the level of endotoxin and
inflammation markers (such as TNF-α) was reduced [120]. These findings led to the consideration of
the hypothesis of probiotics being promising candidates for endotoxemia treatments.
Probiotics also affect the heterocyclic aromatic amines (HCA), which, once exposed to high
temperature, become converted to active derivatives that induce tumorigenic mutations. This process
primarily relates to the ingestion of meat stewed at high temperatures. Related studies concluded that
binding or disintegration of HCA, by probiotics, may be one principle mechanism for eliminating
these oncogenic factors from the body [118].
Engineered Microbes Therapy
The recombinant expression of therapeutic biomolecules, from engineered microbes, perhaps raise
these benefits and assist in the alleviation of inflammation, inhibit infection, and cure metabolic
disorders. Bacteria may develop to deliver drugs at the location of the illness, boosting bioavailability
and minimizing drug inactivation. Moreover, the aforementioned bacteria may be equipped
with sensors which reveal disease biomarkers and trigger on-demand drug release. Completely
independent, “smart” cell-based therapeutics, aimed at restoring the health of a human host have
not yet been developed, clinically, but the essential technologies are accessible. The main defiance in
creating microbiota-based therapeutics is the pinpointing and customization of bacterial communities
to treat complex human illnesses, in spite of the variety of human-associated microbiota [104].
One implementation of engineered bacteria is to treat bacterial and viral infections. The normal
flora existing in healthy people is able to withstand host colonization by pathogens, and cellular
engineering can increase such withstanding [104].
Hyperammonemia is a further metabolic provision, for which engineering the microbiota
might be established effectively. In the gut, bacterial ureases convert urea made by the liver to
ammonia (NH3) and carbon dioxide (CO2). Hyperammonemia take place when excessive ammonia
assembles systemically and give rise to neurotoxicity and encephalopathy, in the liver-diseased
individuals. In mouse models, reconstituting the microbiota modified the community-wide urea
metabolism [121]. After depletion of the endogenous microbiota and transplantation of a defined
microbial community that manifest low urease activity, it was shown that the urease levels remained
stable for months [121]. The redefined microbiota enhanced survival and decreased cognitive defects
linked with hyperammonemia, in a hepatic injury model. Consequently, modifying an existing
microbial community may protect against, in opposition to metabolic diseases. Moreover, microbes
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have been genetically-engineered to degrade ammonia and are shown to decrease the levels of systemic
ammonia, while being fed to mice, like those therapies that are presently being developed by firms, for
clinical attempts [122,123]. Other uses of normal flora cellular engineering are summarized in Table 2.
Table 2. Genetically-engineered normal bacterial flora and their possible therapeutic applications.
Genetically Modified Bacteria Role In Vivo Model
Probiotic E. coli nissle • Prophylaxis: inhibition of Vibrio cholera virulence. • Mouse
Lactobacillus jensenii
• Prevent transmission of chimeric simian/ human
immunodeficiency virus (SHIV). • Rhesus macaque
Lactococcus lactis
• Suppress pro-inflammatory cytokine secretion: by secretion of
recombinant interleukin-10 (IL-10).
• Treatment of autoimmune diabetes: by further modification of this
IL-10 secreting L. lactis to produce auto-antigen proinsulin or
glutamic acid decarboxylase-65.
• Mouse
Lactococcus lactis • Treatment of oral mucositis: by secretion of trefoil factor-1. • Hamster
Probiotic E. coli
• Reduction of obesity: via synthesizing anorexigenic
lipids precursors. • Mouse
Lactobacillus gasseri
• As glucagon-like peptide (GLP-1) delivery vehicle: to induce
conversion of intestinal epithelial cells into insulin-producing cells. • Rat
5.1.2. Subtractive Approaches
Subtractive therapies attempt to remove harmful members of the microbiome, utilizing approaches
like antibiotics, chemicals, peptides, and bacteriophages [104].
Antibiotic Therapy
Antibiotics, a key example of the subtractive therapies that show effectiveness on the human
microbiome. Antibiotic rifaximin’s influence on the microbiome has been deeply detailed. In fact,
a recent study demonstrated that an eight weeks oral administration (twice/day) of 550 mg rifaximin,
in patients affected by cirrhosis, caused a reduction in the microbiota community shift, settlement,
and metabolism [124,125]. Several scientific studies have suggested rifaximin’s ability to modify
microbiota and, thereby, reducing inflammation, as its administration has been documented to improve
life quality in cirrhotic patients [126,127].
Unfortunately, antibiotics frequently have the unfavorable influence of killing a wide set of
microbes outside of the desired target. This can lead to diverse side-effects, like increased susceptibility
to pathogenic bacteria, comprising the Clostridium difficile [104]. In the not so distance future,
subtractive therapies for the microbiome should be much more specified in therapeutic activity.
Phage Therapy
One approach for quite specified subtractive therapies utilizes phages, which, are natural viral
parasites-infecting bacteria, frequently killing the bacterial host, in the production of the phage
progeny operation. The growing threat of antibiotic-resistant pathogens has rekindled attention in
phage therapy [127,128], particularly taking into consideration that phages, frequently, particularly
attack, exclusively one or a few cell types of bacteria, and, consequently, can be applied as more
targeted antimicrobials [104].
Alongside using natural phage isolates, phages can be adjusted to hold additional or alternative
functions to broaden their uses. Immunoglobulin-like protein domains on the capsids of specific
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phages’ exterior, increase the association with mucus [129], a mechanism that may possibly be
utilized to localize phage to certain parts of the body or to broaden residence time in the gut.
Host range might be reprogrammed to change the bacterial targets [130] and genes can be introduced
to ameliorate the biofilms bacteria killing outcome [131]. Moreover, phages have been utilized to
transport DNA to bacteria that reverses the antibiotic resistance [132,133] or to achieve nonspecific [134]
or sequence-specific [135,136] antimicrobial activity to the targeted cells. Recently developed tools like
CRISPR-Cas [137] genome editing and construction approaches, involving Gibson [138] and yeast [130]
assembly, will expedite the not so-distance future engineering attempts. Phages, as therapeutics for
microbiota-associated diseases, act as a hopeful and encouraging field of exploration and utilizing them
as tools to modify the microbial communities may enable the systematic probing of the aforementioned
populations for innovation and justifiability, in both the health investigation and the microbiome [104].
5.2. Oral Microbiota Transplant
It is well-known that periodontitis is closely-related to a dysbiosis of the microbial
consortia, driven by environmental changes, such as a protein-rich/neutral-to-weakly alkaline-pH
environments [7–9].
In periodontitis, certain members of the microbial community can destabilize the host immune
response, which might result in the destruction of the periodontal tissues, in susceptible individuals.
Conventional therapies for periodontitis aim at controlling the formation and metabolic activities of
the supra- and subgingival biofilms [139]. Oral microbiota transplant (OMT) has been hypothetically
proposed by few dental researchers.
Authors suggested an OMT procedure consisting of: (1) Collecting sub- and supra-gingival plaque
from a healthy donor (spouse or a partner), (2) performing deep cleaning, root planning, and applying
a broad-spectrum antimicrobial agent to the periodontitis patient, and finally (3) Neutralizing the
antimicrobial agent, immediately, followed by a rinsing with a microbial suspension, harvested from
the healthy donor in the periodontitis patient [140].
Despite the scanty scientific and clinical evidence, oral microbiota transplant has held promise
as a new therapy for managing periodontitis, as well as caries, and some associated systemic
conditions. This is because recent epidemiological investigations have identified an increased PC-risk
in association with poor oral health conditions [50–54], accompanied by elevated levels of blood
serum antibodies for select oral pathogens—namely, P. gingivalis [56] as well as higher levels of
genotype fimbrillin P. gingivalis—in the saliva of patients affected by cirrhosis [83]; OMT however
is not exempted by limitations, as safety might not have been secured. The transplanted biofilm
should be of a high genetic-stability and should not transmit infection or induce disease. Although
this technique is still theoretical, the potential adverse effects concerning those associated with fecal
microbiota transplantation (FMT), could be taken into account; these effects may include transmission
of infection/pathogen or induction of a chronic disease by potential microbial alteration [141].
OMT may represent a cost-effective approach and have the ability to better reach difficult to
access high-risk populations. However, clinical recommendations for the use of OMT cannot be
provided at this point, on the basis of the current state of knowledge. It is crucial to have a better
understanding of the retentiveness of the transplanted oral biofilms, while maintaining the natural
balance of the resident oral microbiota, with the host immune responses. The already understood
issues include optimal donor selection, sample preparation, vehicles, follow-up timing, and the number
of administrations [139].
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IgA Immunoglobulin A
IgG Immunoglobulin G
IgM Immunoglobulin M
PC: Pancreatic cancer
BMI Body mass index
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ALD Alcoholic liver disease
NAFLD Nonalcoholic fatty liver disease
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HSCs Hepatic stellate cells
TNF Tumor necrosis factor
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PPI: Proton pump inhibitor
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